Takeda Pharmaceutical Company Limited - SIC # 7321 -

Ticker Exchange SIC # Website Latest Ticker
TAK New York 7321 www.takeda.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Takeda Pharmaceutical Company Limited

Sen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001 - Dec 11th, 2025 6:32 am
Sen-Jam Pharmaceutical Appoints Global Life Sciences Leader Rute Fernandes as Executive Advisor to Accelerate Commercialization Pathways - Dec 9th, 2025 6:38 am
Takeda Pharmaceutical (TSE:4502): Reassessing Valuation After Recent Share Price Strength - Dec 7th, 2025 1:05 pm
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - Dec 6th, 2025 7:30 am
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory - Dec 5th, 2025 2:21 pm
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Dec 5th, 2025 7:56 am
Takeda and Innovent fulfil close conditions for ADC and IO therapies - Dec 5th, 2025 3:19 am
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies - Dec 4th, 2025 4:38 pm
insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors - Dec 3rd, 2025 8:30 am
Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsight - Dec 2nd, 2025 3:31 pm
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - Nov 25th, 2025 2:00 pm
Takeda Pharmaceutical (TSE:4502): Exploring Valuation After Recent Shareholder Gains - Nov 22nd, 2025 4:12 pm
Takeda Pharmaceutical's Adzynma Under US FDA Probe Following Death of Pediatric Patient - Nov 21st, 2025 7:50 am
Pouchitis Market Research and Forecast Report 2025-2035: Takeda, Ocera Therapeutics, Exegi Pharma, and Atlantic Pharmaceuticals Lead Through Innovation, Partnerships, and Product Diversification - Nov 19th, 2025 8:22 am
Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery - Nov 19th, 2025 4:30 am
Hemophilia Research Analysis Report 2025-2035: Market Advances as Leading Players Accelerate Gene Therapy Innovation and Strategic Partnerships, Led by CSL Behring, Takeda, and Pfizer - Nov 18th, 2025 8:30 am
Hemophilia A Research Report 2025-2035: Market Driven by Innovation from Alnylam, Pfizer, Roche, Novo Nordisk, and Takeda as Next-Generation Therapies and Emerging Market Expansion Bolsters Growth - Nov 18th, 2025 8:12 am
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy - Nov 7th, 2025 9:00 am
Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players - Nov 6th, 2025 8:23 am
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights - Nov 6th, 2025 6:00 am